Full text
Earnings transcript
Read the complete earnings call transcript.
CHD
Church & Dwight Co., Inc.
$92.85
0
(0%)
| Exchange: | NYSE |
| Market Cap: | 21.994B |
| Shares Outstanding: | 234.883M |
About The Company
| Sector: | Consumer Defensive | |||||
| Industry: | Household & Personal Products | |||||
| CEO: | Richard A. Dierker | |||||
| Full Time Employees: | 5750 | |||||
| Address: |
| |||||
| Website: | https://churchdwight.com |
Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L’IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 5,867,900 | 6,107,100 | 6,203,200 |
| Gross Profit | 2,588,500 | 2,790,100 | 2,774,800 |
| EBITDA | 1,303,500 | 1,090,400 | 1,299,500 |
| Operating Income | 1,057,400 | 807,100 | 1,077,600 |
| Net Income | 755,600 | 585,300 | 736,800 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 8,569,200 | 8,883,100 | 8,912,400 |
| Total Liabilities | 4,713,800 | 4,522,300 | 4,910,200 |
| Total Stockholders Equity | 3,855,400 | 4,360,800 | 4,002,200 |
| Total Debt | 2,605,600 | 2,405,500 | 2,205,100 |
| Cash and Cash Equivalents | 344,500 | 964,100 | 409,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,030,599.999 | 1,156,200 | 1,215,400 |
| Capital Expenditure | -223,500 | -179,800 | -122,400 |
| Free Cash Flow | 807,099.999 | 976,400 | 1,093,000 |
| Net Income | 755,600 | 585,300 | 736,800 |
| Net Change in Cash | 74,200 | 0 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 7,090,004.603 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 7,323,533.045 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 7,138,192.587 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,441,296.684 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,488,769.681 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,451,092.613 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 1,139,644.846 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,188,541.491 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,149,734.436 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,786,480.912 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 1,845,323.484 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,798,622.923 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 4.710 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 4.870 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 4.660 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 7 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates CHD intrinsic value between $58.19 – $106.10 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CHD valuation
Is CHD (CHD) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for CHD (CHD) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CHD a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CHD trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CHD’s P/E ratio?
You can see CHD’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CHD?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CHD a good long-term investment?
Whether CHD fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CHD
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0
Chart data temporarily unavailable.
Daily snapshotTrading Metrics:
| Open: | — | Previous Close: | — | |
| Day Low: | — | Day High: | — | |
| Year Low: | Year High: | |||
| Price Avg 50: | Price Avg 200: | |||
| Volume: | Average Volume: | |||
| Session data unavailable | ||||
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
Relevant news
